GlaxoSmithKline (GSK)'s Advair Sees Sales Slip As Competitors Reach Market
2/5/2014 7:04:49 AM
GlaxoSmithKline’s best-selling drug Advair is losing its share of the US respiratory market to competing products from AstraZeneca and Merck as well as to the company’s new treatment, Breo. Advair’s prescription market share has fallen to 61.6 per cent for the week ended January 24th, compared with 67.2 per cent for the week ended October 25th, according to the most recent data compiled by Bloomberg and Symphony Health Solutions. Growing demand for AstraZeneca’s Symbicort, which has a market share of 30 per cent, and Merck’s Dulera, with an 8.4 per cent share, have eaten into Advair sales, which were £2.5 billion (€3 billion) in the US in 2012.
Help employers find you! Check out all the jobs and post your resume.
comments powered by